TABLE 3.

NSCLC clinical trials with miRNA-based therapy.

miRNA	drug	Population	Number	Toxicities	Safety (≥G3,%)	Efficacy	Status	References
miR-16	TargomiRs, MesomiR-1 trial (NCT02369198)	NSCLC,MPM	27	Infusion-related inflammatory symptoms, coronary ischemia, anaphylaxis, cardiomyopathy, non-cardiac pain	lymphopenia (42), increased AST or ALT (19), temporal hypophosphatemia (15), infusion-related inflammatory symptoms (8), cardiomyopathy (4)	ORR: 5%, SD: 68%, DOR: 32 weeks	Completed	Van Zandwijk et al. (2017)
miR-34	MRX34 (NCT01829971)	NSCLC,SCL,HCC,RCC,GIST, Melanoma	85	Hypoxia, neutropenia, thrombocytopenia	SAEs (35), lymphopenia (18), chills (14), deaths (9), fatigue (9), neutropenia (8), thrombocytopenia (6), back/neck pain (5), dyspnea (5)	ORR: 4%, SD for ≥4 cycles: 24%	Early closed	Hong et al. (2020)

HCC, hepatocellular carcinoma; RCC, renal cell carcinoma; GIST, gastrointestinal stromal tumor; SAEs, severe adverse events; ORR, objective response rate; SD, stable disease; MPM, malignant pleural mesothelioma; AST, aspartate aminotransferase; ALT, alanine aminotransferase; DOR, duration of the objective response.